Position in DNLI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$1,579,208
+$450,652 QoQ
Shares Held
61,400
+4.5% QoQ
Ownership
0.038%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#103
of 290 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Vanguard Global Advisers, LLC holds $817,850,037 across 371 Biotechnology names. DNLI ranks #49 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
547,463 | $271,941,295 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
226,724 | $141,371,482 | |
| 3 | MRNA |
Moderna, Inc.
|
737,973 | $51,680,249 | |
| 4 | INCY |
Incyte Corp
|
380,037 | $43,080,994 | |
| 5 | TECH |
BIO-TECHNE Corp
|
324,090 | $22,896,958 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
64,254 | $19,342,381 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
82,088 | $15,373,440 | |
| 8 | RPRX |
Royalty Pharma plc
|
230,477 | $12,922,845 |
All Filings in DNLI
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,579,208 | 61,400 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $1,128,556 | 58,779 | Shares | Defined | 2026-05-08 | |
| No filing history on record for this holder in this stock. | ||||||